Attendee Testimonials

Hear What Leaders in the Field are Looking Forward to at the mRNA-Based Therapeutics Summit

Yusuf Erkul

“The mRNA-Based Therapeutics Summit brings together industry leaders and academic pioneers. The summit represents a great venue for sharing scientific developments and intellectual perspectives on mRNA medicine.”

Yusuf Erkul

CEO, Kernal Biologics

Kernal bio
Gregory Fiore

“The field is moving so quickly it is only possible to keep updated on the pace and progress through participation in forums such as this where conversations take place with those making the advancements.” 

Gregory Fiore

CEO, Exacis Biotherapeutics

exacis
Linda Marban

“This event brings together thought leaders across the industry to discuss their unique perspectives in this growing field and we look forward to sharing our insights.”

Linda Marban

CEO, Capricor Therapeutics

Cparicor
Joe Payne

“This event creates a forum for the mRNA community to come together to share ideas and latest technologies in the industry.”

Joe Payne

Founder, President & CEO, Arcturus Therapeutics

Arcuturs
Akhliesh

"This forum serves as an excellent opportunity to share unique perspectives from key thought leaders on various ongoing innovations in the field of mRNA delivery and we look forward to sharing our insights"

Akhilesh Bhambhani 

Senior Director - Biologics Drug Product Development; Tech Dev/Tech Ops, Ultragenyx

logo-ultragenyx
Rituparna Das

"This summit will allow us to understand how the experience with vaccines, particularly COVID vaccines which have been used by millions of people around the world, can further the field of mRNA technology and it’s use as prevention and therapeutic measures"

Rituparna Das

VP – COVID Vaccines, Moderna

MODERNA
Jenny Van

"The meeting provides a stimulating platform to interact with experts in this emerging field and share thoughts and ideas that may shape the future of mRNA therapeutics"

Jenny van Asbeck - van der Wijst 

CEO, Mercurna

Mercuna
Kalina Paunovska

“At this summit, I see value in learning about current non-viral vector preclinical bottlenecks such as toxicity and manufacturing. I am also interested in hearing how current nucleic acid therapeutics companies plan on tackling non-liver delivery.”

Kalina Paunovska

Postdoctoral Scholar, Georgia Institute of Technology, Dahlman Lab

Dahlman
Russel Johnson

“This summit is an excellent opportunity to join in the discussion with key thought leaders and innovators of one of the most impactful technologies of this generation.”

Russell Johnson

VP – Formulation Research, RVAC Medicines

RVAC
John Marshall

“mRNA as a platform therapeutic has held promise for many years, but it is only recently that it has reached the people who can benefit from it. This meeting can help inform and differentiate from other genetic therapies and identify opportunities for synergy.”

John Marshall

Senior Director – Rare Disease, Moderna

MODERNA